Get the Stockscreener App
5.96
2.77%
-0.17
Tempest Therapeutics Inc stock is traded at $5.96, with a volume of 23,658.
It is down -2.77% in the last 24 hours and down -16.17% over the past month.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
See More
Previous Close:
$6.13
Open:
$6.01
24h Volume:
23,658
Relative Volume:
0.46
Market Cap:
$21.93M
Revenue:
-
Net Income/Loss:
$-31.11M
P/E Ratio:
-3.8954
EPS:
-1.53
Net Cash Flow:
$-28.18M
1W Performance:
-4.33%
1M Performance:
-16.17%
6M Performance:
-51.74%
1Y Performance:
-86.02%
1-Day Range:
$5.92
$6.079
1-Week Range:
$5.92
$6.44
52-Week Range:
$5.3495
$44.59
Tempest Therapeutics Inc Stock (TPST) Company Profile
Name
Tempest Therapeutics Inc
Sector
Industry
Phone
415-798-8589
Address
2000 SIERRA POINT PARKWAY, BRISBANE
Compare TPST with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TPST
Tempest Therapeutics Inc
|
5.96 | 23.16M | 0 | -31.11M | -28.18M | -1.53 |
|
ONC
Beone Medicines Ltd Adr
|
246.59 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.48 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.32 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
80.61 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
491.63 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Tempest Therapeutics Inc Stock (TPST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-10-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-14-24 | Initiated | Scotiabank | Sector Outperform |
| Feb-08-24 | Initiated | Jefferies | Buy |
Tempest Therapeutics Inc Stock (TPST) Latest News
Tempest Therapeutics Reports Q1 2025 Financial Results - TipRanks
HC Wainwright Issues Optimistic Estimate for TPST Earnings - Defense World
Tempest Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Layoff Tracker: Allogene Cuts 28% of Staff to Extend Runway, Focus on Clinical Programs - BioSpace
TPST Highlights Promising Data for Cancer Therapy | TPST Stock N - GuruFocus
Tempest Therapeutics Q1 Operating Income USD -10.936 Million - marketscreener.com
Tempest Therapeutics Reports Positive Amezalpat Data and FDA Designations for Cancer Treatment Programs - Nasdaq
Tempest Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
FDA Grants Multiple Key Designations to Tempest Cancer Drugs as New AACR Data Shows Promise - Stock Titan
Millendo Therapeutics, Inc. Announces Board Changes - marketscreener.com
Cash-strapped Bay Area biotech company lays off all but 5 employees - MSN
Tempest Therapeutics Inc expected to post a loss of $3.29 a shareEarnings Preview - TradingView
Geode Capital Management LLC Has $296,000 Stake in Tempest Therapeutics, Inc. (NASDAQ:TPST) - Defense World
XTX Topco Ltd Has $134,000 Position in Tempest Therapeutics, Inc. (NASDAQ:TPST) - Defense World
Tempest Therapeutics regains Nasdaq compliance By Investing.com - Investing.com Canada
Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting - The Manila Times
Tempest Therapeutics Presents Promising Amezalpat Data at 2025 AACR Annual Meeting, Supporting Novel Cancer Treatment Mechanism - Nasdaq
Tempest Presents New Amezalpat MOA Data Reinforcing Its - GlobeNewswire
Breakthrough: New Cancer Drug Amezalpat Demonstrates Dual Anti-Cancer Mechanism in Multiple Tumors - Stock Titan
Tempest Therapeutics regains Nasdaq compliance - Investing.com
Market Recap Check: Tempest Therapeutics Inc (TPST)’s Negative Finish at 0.61, Up/Down -14.53 - DWinneX
Struggling Bay Area biotech company, once worth $1B, lays off all but 5 workers - SFGATE
Tempest Therapeutics - The Pharma Letter
Tempest Therapeutics stock rises on FDA Orphan Drug Designation By Investing.com - Investing.com Nigeria
Tempest Therapeutics stock rises on FDA Orphan Drug Designation - Investing.com Australia
Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP - The Manila Times
FDA Awards Rare Disease Drug Status to Tempest's Novel FAP Treatment: Phase 2 Trial Coming in 2025 - Stock Titan
Tempest to explore alternatives to advance promising pipeline - The Pharma Letter
TPST to Evaluate Strategic Options for Pipeline Studies, Stock Up - MSN
Scotiabank Reaffirms “Sector Perform” Rating for Tempest Therapeutics (NASDAQ:TPST) - Defense World
HC Wainwright Reaffirms Neutral Rating for Tempest Therapeutics (NASDAQ:TPST) - Defense World
Tempest Therapeutics Retail Chatter Explodes As Cancer Drug Developer Mulls Possible Merger - Asianet Newsable
Tempest Weighs M&A, Analyst Sees A "Broken Story" Despite Phase 2 Liver Cancer Study Success - Benzinga
Tempest seeks strategic alternatives as cash runs out for Phase 3 trial - BioPharma Dive
HC Wainwright Downgrades Tempest Therapeutics to Neutral From Buy - marketscreener.com
Tempest hits funding block for Phase III liver cancer drug-in-waiting - Yahoo Finance
Tempest seeks strategic alternatives to fund Phase 3 liver cancer trial - Endpoints News
Tempest Therapeutics evaluates strategic options amid advancements By Investing.com - Investing.com South Africa
Tempest Therapeutics Terminates Loan Agreement with Oxford - TipRanks
Tempest Therapeutics Seeks Partner as It Explores Strategic Alternatives - marketscreener.com
Tempest Therapeutics Mulls Alternatives to Advance Cancer Treatment Programs - marketscreener.com
Tempest Therapeutics evaluates strategic options amid advancements - Investing.com
Tempest Announces Plan to Explore Strategic Alternatives to - GlobeNewswire
Tempest Therapeutics announces 1-for-13 reverse stock split - Investing.com Australia
Tempest Therapeutics announces 1-for-13 reverse stock split By Investing.com - Investing.com Canada
Tempest Therapeutics Inc Stock (TPST) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tempest Therapeutics Inc Stock (TPST) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Versant Venture Capital VI, L. | 10% Owner |
Aug 08 '24 |
Sale |
1.35 |
400,000 |
540,040 |
597,940 |
| Versant Venture Capital VI, L. | 10% Owner |
Aug 12 '24 |
Sale |
1.10 |
387,999 |
426,993 |
209,941 |
2.38%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):